BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 38653778)

  • 21. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
    Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
    Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma.
    Weng Z; Lin J; He J; Gao L; Lin S; Tsang LL; Zhang H; He X; Wang G; Yang X; Zhou H; Zhao H; Li G; Zou L; Jiang X
    Neuro Oncol; 2022 Jun; 24(6):872-885. PubMed ID: 34655293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
    Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
    Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MYCN Directly Targets NeuroD1 to Promote Cellular Proliferation in Neuroblastoma.
    Lu F; Mu B; Jin G; Zhu L; Mu P
    Oncol Res; 2022 May; 29(1):1-10. PubMed ID: 34937609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry.
    Wang L; Tan TK; Durbin AD; Zimmerman MW; Abraham BJ; Tan SH; Ngoc PCT; Weichert-Leahey N; Akahane K; Lawton LN; Rokita JL; Maris JM; Young RA; Look AT; Sanda T
    Nat Commun; 2019 Dec; 10(1):5622. PubMed ID: 31819055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The transcription factor protein Sox11 enhances early osteoblast differentiation by facilitating proliferation and the survival of mesenchymal and osteoblast progenitors.
    Gadi J; Jung SH; Lee MJ; Jami A; Ruthala K; Kim KM; Cho NH; Jung HS; Kim CH; Lim SK
    J Biol Chem; 2013 Aug; 288(35):25400-25413. PubMed ID: 23888050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wnt Signalling Drives Context-Dependent Differentiation or Proliferation in Neuroblastoma.
    Szemes M; Greenhough A; Melegh Z; Malik S; Yuksel A; Catchpoole D; Gallacher K; Kollareddy M; Park JH; Malik K
    Neoplasia; 2018 Apr; 20(4):335-350. PubMed ID: 29505958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry.
    Durbin AD; Zimmerman MW; Dharia NV; Abraham BJ; Iniguez AB; Weichert-Leahey N; He S; Krill-Burger JM; Root DE; Vazquez F; Tsherniak A; Hahn WC; Golub TR; Young RA; Look AT; Stegmaier K
    Nat Genet; 2018 Sep; 50(9):1240-1246. PubMed ID: 30127528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression and activation of nuclear hormone receptors result in neuronal differentiation and favorable prognosis in neuroblastoma.
    Sainero-Alcolado L; Mushtaq M; Liaño-Pons J; Rodriguez-Garcia A; Yuan Y; Liu T; Ruiz-Pérez MV; Schlisio S; Bedoya-Reina O; Arsenian-Henriksson M
    J Exp Clin Cancer Res; 2022 Jul; 41(1):226. PubMed ID: 35850708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The long noncoding RNA LINC00200 promotes the malignant progression of MYCN-amplified neuroblastoma via binding to insulin like growth factor 2 mRNA binding protein 3 (IGF2BP3) to enhance the stability of Zic family member 2 (ZIC2) mRNA.
    Chen J; Sun M; Huang L; Fang Y
    Pathol Res Pract; 2022 Sep; 237():154059. PubMed ID: 35969939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calreticulin regulates MYCN expression to control neuronal differentiation and stemness of neuroblastoma.
    Lee AC; Shih YY; Zhou F; Chao TC; Lee H; Liao YF; Hsu WM; Hong JH
    J Mol Med (Berl); 2019 Mar; 97(3):325-339. PubMed ID: 30612140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HMGI(Y) and HMGI-C genes are expressed in neuroblastoma cell lines and tumors and affect retinoic acid responsiveness.
    Giannini G; Di Marcotullio L; Ristori E; Zani M; Crescenzi M; Scarpa S; Piaggio G; Vacca A; Peverali FA; Diana F; Screpanti I; Frati L; Gulino A
    Cancer Res; 1999 May; 59(10):2484-92. PubMed ID: 10344762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The all-trans retinoic acid (atRA)-regulated gene Calmin (Clmn) regulates cell cycle exit and neurite outgrowth in murine neuroblastoma (Neuro2a) cells.
    Marzinke MA; Clagett-Dame M
    Exp Cell Res; 2012 Jan; 318(1):85-93. PubMed ID: 22001116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
    Yang XH; Tang F; Shin J; Cunningham JM
    BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.
    Luo P; Lin M; Li L; Yang B; He Q
    PLoS One; 2011; 6(11):e27298. PubMed ID: 22087283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel PAD4/SOX4/PU.1 signaling pathway is involved in the committed differentiation of acute promyelocytic leukemia cells into granulocytic cells.
    Song G; Shi L; Guo Y; Yu L; Wang L; Zhang X; Li L; Han Y; Ren X; Guo Q; Bi K; Jiang G
    Oncotarget; 2016 Jan; 7(3):3144-57. PubMed ID: 26673819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma.
    Lampis S; Raieli S; Montemurro L; Bartolucci D; Amadesi C; Bortolotti S; Angelucci S; Scardovi AL; Nieddu G; Cerisoli L; Paganelli F; Valente S; Fischer M; Martelli AM; Pasquinelli G; Pession A; Hrelia P; Tonelli R
    J Exp Clin Cancer Res; 2022 Apr; 41(1):160. PubMed ID: 35490242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CDK5RAP3 is a novel super-enhancer-driven gene activated by master TFs and regulates ER-Phagy in neuroblastoma.
    Zhuo R; Zhang Z; Chen Y; Li G; Du S; Guo X; Yang R; Tao Y; Li X; Fang F; Xie Y; Wu D; Yang Y; Yang C; Yin H; Qian G; Wang H; Yu J; Jia S; Zhu F; Feng C; Wang J; Xu Y; Li Z; Shi L; Wang X; Pan J; Wang J
    Cancer Lett; 2024 Jun; 591():216882. PubMed ID: 38636893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of down-regulated neutral ceramidase during all-trans retinoic acid-induced neuronal differentiation in SH-SY5Y neuroblastoma cells.
    Tanaka K; Tamiya-Koizumi K; Hagiwara K; Ito H; Takagi A; Kojima T; Suzuki M; Iwaki S; Fujii S; Nakamura M; Banno Y; Kannagi R; Tsurumi T; Kyogashima M; Murate T
    J Biochem; 2012 Jun; 151(6):611-20. PubMed ID: 22451680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The transcriptional repressor SNAI2 impairs neuroblastoma differentiation and inhibits response to retinoic acid therapy.
    Vrenken KS; Vervoort BMT; van Ingen Schenau DS; Derks YHW; van Emst L; Grytsenko PG; Middelbeek JAJ; van Leeuwen FN
    Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165644. PubMed ID: 31862304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.